The Non-Small Cell Lung Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non-Small Cell Lung Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non-Small Cell Lung Carcinoma and features dormant and discontinued products.
GlobalData tracks 79 drugs in development for Non-Small Cell Lung Carcinoma by 68 companies/universities/institutes. The top development phase for Non-Small Cell Lung Carcinoma is preclinical with 28 drugs in that stage. The Non-Small Cell Lung Carcinoma pipeline has 72 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Non-Small Cell Lung Carcinoma pipeline products market are: Xiangxue Life Sciences, AstraZeneca and U.S. National Institutes of Health.
The key targets in the Non-Small Cell Lung Carcinoma pipeline products market include Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor ERB1, and Hepatitis A Virus Cellular Receptor 2.
The key mechanisms of action in the Non-Small Cell Lung Carcinoma pipeline product include Programmed Cell Death Protein 1 Antagonist with eight drugs in Phase III. The Non-Small Cell Lung Carcinoma pipeline products include 13 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Non-Small Cell Lung Carcinoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Non-Small Cell Lung Carcinoma overview
Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC doesn’t tend to spread as fast as SCLC and has a better survival rate.
For a complete picture of Non-Small Cell Lung Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
